New lupus drug shows promise in early trial

NCT ID NCT02472795

Completed Disease control Sponsor: Viatris Innovation GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tested a new drug called cenerimod in 105 people with systemic lupus erythematosus (SLE), an autoimmune disease. The goal was to see if the drug could safely lower certain immune cells (lymphocytes) in the blood, which may help control the disease. Participants continued their usual lupus medications during the trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Investigator Site

Anniston, Alabama, 36207, United States
Investigator Site

Clearwater, Florida, 33765, United States
Investigator Site

Minsk, 220116, Belarus
Investigator Site

Minsk, 223041, Belarus
Investigator Site

Vitebsk, 210037, Belarus
Investigator Site

Plovdiv, 4000, Bulgaria
Investigator Site

Plovdiv, 4002, Bulgaria
Investigator Site

Sofia, 1612, Bulgaria
Investigator Site

Tbilisi, 0186, Georgia
Investigator Site

Kemerovo, 650066, Russia
Investigator Site

Kursk, 305007, Russia
Investigator Site

Omsk, 644111, Russia
Investigator Site

Orenburg, 460018, Russia
Investigator Site

Smolensk, 214025, Russia
Investigator Site

Vladimir, 600023, Russia
Investigator Site

Vinnytsia, 21018, Ukraine
Investigator Site

Vinnytsia, 21029, Ukraine
Investigator Site

Zaporizhia, 69600, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.